Optimized Prefrontal and Cerebellar Intermittent Theta Burst Stimulation forNegative Symptoms of Schizophrenia (OPCINSS): A Double-Blind Randomized Placebo- Controlled Trial with Imaging and Electrophysiological Outcomes - OPCINSS

ational Institute of Mental Health and Neurosciences NIMHANS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1. Patients diagnosed with schizophrenia as per Diagnostic and Statistical Manual â?? 5 (DSM-5) (American Psychiatric Association, 2013) criteria, aged 18-60 years of either sex will be recruited from the outpatient and inpatient settings of the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
•2. At least one of the domains of negative symptoms should be at least of a moderate severity as indicated by Scale for Assessment of Negative Symptoms (SANS) global score of 3 or more on affective flattening OR alogia OR avolition-apathy OR anhedonia-asociality (Andreasen et al., 2005)
•3. Stable dose of oral antipsychotics (defined as <25% change in dose) for the past 6 weeks and/or parenteral antipsychotics for the past 12 weeks

•1. Significant neurological or medical disorders that may produce cognitive impairment
•2. Substance abuse or dependence (except nicotine) within the past 3 months
•3. Persistent suicidal or homicidal behavior
•4. Pregnant, lactating or in the postpartum state
•5. Self-reported visual or auditory impairment that may interfere with study evaluations
•6. Risk factors for TMS procedures and/or MRI as assessed by standard questionnaires
•(Ghadimi & Sapra, 2020; Rossi et al., 2011)

发起方

ational Institute of Mental Health and Neurosciences NIMHANS